Key Takeaways
- Strong quarter, guidance held: Revenue grew 26% YoY to over ₹295 crores, exports nearly doubled, and management reaffirmed the full-year ₹1,000 crore target, calling H1 delivery exactly in line with commitments.
- Exports are back: Export sales jumped to ₹140 crores from ₹74 crores a year ago, driven by easing global destocking, personal customer visits across geographies, and cost competitiveness that is winning share from China.
- Margins in the promised band: EBITDA margin expanded to 18.3% from 16.6% a year ago, and management expects to hold the 18%-20% range through H2 and into FY27.
- The ₹3,000 crore ambition is now scaffolded: A board-approved backward integration project, Shalvis starting production, and a capex pipeline funded entirely from internal accruals all point toward the FY30-31 target.
- What to watch next quarter: Whether PEDA expansion comes online on time, the pace of Shalvis’s molecule additions, and any quantification of the backward integration margin benefit that management has so far called strategic rather than numerical.
Export Recovery & Demand Drivers
- Volume and value both up: Exports rose from ₹74 crores to ₹140 crores YoY, driven by technical material and bulk formulation sales to customers who are shifting orders back from China on cost and reliability grounds.
- Personal engagement unlocked orders: Management visited customers across Australia, Europe and the USA, crediting the personal touch with securing increased orders; the company also gained market share in import-substitution molecules like PEDA, where it now caters to over 90% of domestic demand that was previously imported.
- Bulk formulation is sticky, not a one-off: Customers prefer buying bulk formulation to reduce their own formulation costs abroad, and management says the orders are regular and sustainable.
- Utilization confirms the trend: Technical utilization moved meaningfully above 73% as global destocking eases and demand visibility improves.
D.K. Jain: "We have visited a lot of our customers in their factories and offices across the world, including Australia, Europe, U.S.A., etc. And that has given a more personal touch to the business, and that's how we have got increased orders from our various customers across the geographies."
Domestic & Seasonal Dynamics
- Monsoon was a mixed bag: Heavy rains washed off pests and kept domestic revenue marginally lower at ₹150 crores, but the extended monsoon set up favorable moisture and sowing conditions for the Rabi season, which management expects to drive a strong H2.
- Seasonal pattern holds: First half typically contributes 55% of annual turnover because domestic sales concentrate there; second half is 44%-45% as exports carry the weight while domestic moves into the Rabi-only window.
- Pretilachlor is deeply seasonal: Sold only up to June, with technical sales mostly complete by then; Q2 has hardly any Pretilachlor revenue, and management expects a minimum of ₹250 crores from Pretilachlor and its intermediate in FY27.
Capacity Expansion & Backward Integration
- Formulation capacity already scaled: The formulation facility output increased from 6,500 MT to 10,000 MT, supporting the rising mix of bulk formulation sales, which reached 34% of revenue in Q2 versus 27%-28% last year.
- Backward integration into 2,6-DEA approved: The board sanctioned a ₹65 crore project at Sandila to produce 4,000 MT of 2,6-DEA, a key intermediate for forward-integrated molecules the company already makes; management calls it strategic for reducing import dependence and improving overall product margins, though it did not quantify the margin accretion.
- PEDA expansion nearly there: The expansion to 8,000-8,500 MT was delayed by heavy monsoon in Lucknow but will be on stream in 15-20 days; management expects full capacity utilization by next year.
- Capex is fully internally funded: The company remains zero-debt, with all growth funded through internal accruals; the ₹116 crores of capex currently underway will contribute from next financial year.
D.K. Jain: "That is more of a strategic nature in the sense we want to reduce our dependence on the import of this material because we are already making the forward integrated molecules from this."
Shalvis Specialities Progress
- Production has begun: Shalvis started technical grade production of one molecule in a small way after initial infrastructure delays; one block of technical grade insecticide and fungicide is under construction and will be commissioned shortly, while a semi-commercial pilot plant is already making small quantities of another product.
- Revenue contribution next year: Management expects Shalvis to contribute around ₹100 crores in revenue next year from two blocks, with average margins estimated at 18%-20% and possibly slightly higher depending on product type.
- Market access is ready: Customers have already agreed to buy, so Shalvis can start selling immediately after production; the company is working on multiple molecules going off patent and will introduce at least two new molecules next year, with revenue from those two expected at 2x the capex invested.
Margins & Working Capital
- Margin walk: EBITDA margin expanded to 18.3% from 16.6% YoY, driven by better operating leverage and cost improvements; QoQ margins were flat because Q1 included over ₹2 crores of other income from an insurance claim, and excluding that, margins inched up slightly to the projected 18%.
- H2 margin commitment: Management expects to maintain EBITDA margins between 18% and 20% irrespective of sales revenue in H2, and sees the same 18%-20% band as sustainable for FY27.
- Working capital transformed: Working capital days fell sharply from 255 days in March 2025 to 174 days in September 2025; management targets a further 25-30 day reduction by March 2026, split between at least 20 days from inventory and 10-15 days from receivables.
Long-Term Roadmap to ₹3,000 Crores
- The target: Management aims to scale IPL to ₹3,000 crores in revenue by FY30 or FY31, funded mostly from internal accruals, and says extensive fieldwork and customer meetings underpin its confidence.
- The building blocks: The plan rests on R&D-led innovation in differentiated high-value molecules, deepening the integrated manufacturing footprint, expanding formulation and technical capabilities, and growing Shalvis; the medium-term export mix target is 40%-45% of turnover.
- Capex and split questions remain open: When asked what capex is needed for 3x growth and what the formulation/technical split and margin profile would look like at that scale, management reiterated the 18%-20% margin target and that both capabilities will increase, but did not provide specific capex or mix figures.
- On valuation and buyback: An analyst suggested a buyback given the stock trades well below its ₹296 FPO price; management argued that deploying surplus into business assets and production capacity creates more value, and that valuation will follow once the market recognizes the company's quality, though it agreed to discuss the suggestion internally.
D.K Jain: "Sir, we will try our best. That's what we have aimed at. We have done a lot of field work. We have done a lot of meetings and we are quite confident that by that time, we would be very near to that target."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| FY26 revenue | Approximately ₹1,000 crores; may slightly surpass | FY26 full year |
| FY26 EBITDA margin | Maintain 18%-20% range | H2 FY26 |
| FY27 standalone growth | At least 20% over FY26 | FY27 |
| FY27 EBITDA margin | Sustainable at 18%-20% | FY27 |
| Shalvis revenue contribution | Around ₹100 crores | FY27 (next year) |
| PEDA capacity utilization | Full utilization of 8,500 MT | FY27 (next year) |
| Working capital reduction | Inventory down ≥20 days, receivables down 10-15 days; total 25-30 days further reduction | By March 2026 |
| Pretilachlor and intermediate revenue | Minimum ₹250 crores | FY27 |
| New molecule introductions in Shalvis | At least 2 molecules, revenue at 2x the capex invested | FY27 (next year) |
| Long-term revenue target | ₹3,000 crores | FY30 or FY31 |
Key Metrics
| Metric | Q2 FY26 |
|---|---|
| Revenue | ₹295 crores, +26% YoY |
| H1 FY26 revenue | ₹579 crores, +26% YoY |
| FY26 revenue guidance | ~₹1,000 crores |
| EBITDA | ₹54 crores, +37.6% YoY |
| EBITDA margin | 18.3%, up from 16.6% in Q2 FY25 |
| Net profit | ₹32 crores, +22% YoY |
| PAT margin | 10.7% |
| H1 FY26 EBITDA | ₹108 crores, +53% YoY |
| H1 FY26 EBITDA margin | 18.6% |
| H1 FY26 net profit | ₹67 crores, +48% YoY |
| Export revenue | ₹140 crores, nearly doubled from ₹74 crores in Q2 FY25 |
| Domestic revenue | ₹150 crores, marginally lower YoY |
| Revenue mix (technical/API vs formulation) | 66% technical and API, 34% formulation |
| Technical utilization | over 73% |
| ROCE | 18.8%, up from 17.6% in Q2 FY25 |
| Net cash and cash balance | ~₹80 crores |
| Working capital days | 174 days, reduced from 255 days as at 31 March 2025 |
| Formulation capacity | 10,000 metric tons, expanded from 6,500 metric tons |
| Capex deployed (IPL and Shalvis) | ₹52 crores |
| Shalvis expected revenue next year | ~₹100 crores |
| Long-term revenue target | ₹3,000 crores by FY30-31 |